September 7, 2021
Biosimilar candidate of Fresenius Kabi shows positive results in two clinical trials
Fresenius Kabi has reached a milestone on the road to approval for another biosimilar. MSB11456, a tocilizumab biosimilar candidate, successfully met the primary and secondary endpoints in two consecutively conducted clinical trials. For more information, please visit the Fresenius Kabi website.